share_log

Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 18.8%

Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 18.8%

空頭股數在Inozyme製藥公司(納斯達克代碼：INZY)的跌幅為18.8%
kopsource ·  2022/08/31 17:13

Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 267,000 shares, a decrease of 18.8% from the July 31st total of 328,800 shares. Approximately 1.2% of the company's shares are short sold. Based on an average daily volume of 180,100 shares, the short-interest ratio is presently 1.5 days.

Inozyme Pharma，Inc.(納斯達克：Inzy-Get評級)是空頭股數8月份大幅下跌的目標。截至8月15日，空頭股數共有267,000股，較7月31日的328,800股減少18.8%。該公司約1.2%的股票被賣空。以日均成交量180,100股計算，目前短息比率為1.5天。

Inozyme Pharma Stock Down 0.7 %

Inozyme Pharma股價下跌0.7%

Shares of NASDAQ:INZY traded down $0.02 on Wednesday, hitting $3.03. 1,072 shares of the company traded hands, compared to its average volume of 70,788. The stock has a 50 day simple moving average of $4.11 and a 200-day simple moving average of $4.43. The company has a market cap of $121.65 million, a PE ratio of -1.21 and a beta of 0.09. Inozyme Pharma has a 52 week low of $3.01 and a 52 week high of $17.55.

週三，納斯達克的股價下跌了0.02美元，跌至3.03美元。該公司1,072股易手，而其平均成交量為70,788股。該股的50日簡單移動均線切入位為4.11美元，200日簡單移動均線切入位為4.43美元。該公司市值為1.2165億美元，市盈率為-1.21，貝塔係數為0.09。Inozyme Pharma的52周低點為3.01美元，52周高點為17.55美元。

Get
到達
Inozyme Pharma
Inozyme製藥公司
alerts:
警報：

Analyst Upgrades and Downgrades

分析師升級和下調評級

Several analysts have commented on INZY shares. Wedbush lowered their price objective on shares of Inozyme Pharma from $25.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, May 10th. Jefferies Financial Group assumed coverage on shares of Inozyme Pharma in a report on Thursday, May 26th. They set a "hold" rating and a $5.00 target price on the stock.

幾位分析師對Inzy的股票發表了評論。韋德布什在5月10日(週二)的一份報告中將Inozyme Pharma的股票目標價從25.00美元下調至23.00美元，併為該公司設定了“跑贏大盤”的評級。傑富瑞金融集團在5月26日星期四的一份報告中對Inozyme Pharma的股票進行了報道。他們為該股設定了“持有”評級和5.00美元的目標價。

Hedge Funds Weigh In On Inozyme Pharma

對衝基金參與Inozyme Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of INZY. Adage Capital Partners GP L.L.C. lifted its position in Inozyme Pharma by 8.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,599,028 shares of the company's stock valued at $10,905,000 after purchasing an additional 131,200 shares in the last quarter. Northern Trust Corp raised its holdings in Inozyme Pharma by 4.0% during the fourth quarter. Northern Trust Corp now owns 120,762 shares of the company's stock valued at $823,000 after acquiring an additional 4,661 shares during the period. Suvretta Capital Management LLC lifted its position in shares of Inozyme Pharma by 2.7% in the fourth quarter. Suvretta Capital Management LLC now owns 1,013,216 shares of the company's stock valued at $6,910,000 after acquiring an additional 26,816 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Inozyme Pharma during the second quarter worth about $53,000. Finally, Citigroup Inc. raised its stake in Inozyme Pharma by 241.6% during the 1st quarter. Citigroup Inc. now owns 12,517 shares of the company's stock valued at $51,000 after purchasing an additional 8,853 shares during the period.
幾家對衝基金和其他機構投資者最近買賣了Inzy的股票。Adage Capital Partners GP L.L.C.在第四季度將其在Inozyme Pharma的頭寸提高了8.9%。Adage Capital Partners GP L.L.C.在上個季度額外購買了131,200股後，現在擁有1,599,028股該公司的股票，價值10,905,000美元。北方信託公司在第四季度將其在Inozyme Pharma的持股增加了4.0%。北方信託公司目前擁有120,762股該公司股票，價值823,000美元，在此期間又購買了4,661股。Suvretta Capital Management LLC在第四季度將其在Inozyme Pharma的股票頭寸提高了2.7%。Suvretta Capital Management LLC在上個季度增持了26,816股後，現在擁有1,013,216股該公司股票，價值6910,000美元。Virtu Financial LLC在第二季度購買了Inozyme Pharma的新股，價值約53,000美元。最後，花旗集團在第一季度將其在Inozyme Pharma的持股比例提高了241.6%。花旗集團目前持有該公司12,517股股票，價值51,000美元，在此期間又購買了8,853股。

About Inozyme Pharma

關於Inozyme Pharma

(Get Rating)

(獲取評級)

Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.

Inozyme Pharma，Inc.是一家罕見疾病生物製藥公司，致力於開發治療影響血管系統、軟組織和骨骼疾病的異常礦化的療法。該公司的主要候選產品是INZ-701，這是一種可溶的重組蛋白，用於治療ENPP1和ABCC6缺乏症等罕見的遺傳性疾病，以及治療鈣質缺乏症。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Inozyme Pharma (INZY)
  • Crowdstrike Stock Retraces, As Earnings Sober Expectations
  • Will The Institutions Buy The Dip In Ambarella Stock?
  • PVH Corporation Is On Track For Capital Returns
  • Can Pinterest Rally On Support From Big Investor With Conviction?
  • Chargepoint Rallies, Despite Weaker Earnings
  • 免費獲取StockNews.com關於Inozyme Pharma的研究報告(Inzy)
  • CrowdStrike股價回落，盈利超出預期
  • 這些機構會在安巴雷拉入股抄底嗎？
  • PVH公司有望實現資本回報
  • Pinterest能否堅定地獲得大投資者的支持？
  • ChargePoint上漲，儘管收益疲軟

Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

接受Inozyme Pharma Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Inozyme Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論